Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis
A Population-Based Pharmacokinetic Model of [ 177 Lu]Lu-PSMA-617 for Predicting Organ and Tumor Biodistribution in Prostate Cancer Patients (EANM 2026) - Sep 29, 2026 - Abstract #EP-1242; "This population PK modeling predicts distribution of [¹⁷⁷Lu]Lu-PSMA-617 and its inter-individual variability in prostate cancer patients. Tumor burden was identified as a key driver of uptake kinetics, highlighting its relevance for treatment personalization. The proposed framework supports population-based prediction of radioligand distribution and may facilitate improved dosimetry and therapy optimization." 
Clinical • PK/PD data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Salivary Gland Cancer • Solid Tumor
https://www.sciencedirect.com/science/article/pii/S3051291326002855?via%3Dihub
 
V. Spielmann 1; D. Kupitz 2; W. Li 1; M. Kreißl 2, 3
 
Sep 29, 2026
 
Prev Next